mirvaso Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Mirvaso, and when can generic versions of Mirvaso launch?

Mirvaso is a drug marketed by Galderma Labs Lp and is included in one NDA. There are twelve patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and twenty-four patent family members in thirty-one countries.

The generic ingredient in MIRVASO is brimonidine tartrate. There are eleven drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the brimonidine tartrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Mirvaso

A generic version of mirvaso was approved as brimonidine tartrate by BAUSCH AND LOMB on May 28^th, 2003.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for mirvaso?
What are the global sales for mirvaso?
What is Average Wholesale Price for mirvaso?

Summary for mirvaso

International Patents:	124
US Patents:	12
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	104
Clinical Trials:	12
Patent Applications:	1,636
Drug Prices:	Drug price information for mirvaso
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for mirvaso
What excipients (inactive ingredients) are in mirvaso?	mirvaso excipients list
DailyMed Link:	mirvaso at DailyMed

Drug patent expirations by year for mirvaso

Recent Clinical Trials for mirvaso

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of California, San Francisco	Early Phase 1
Heinrich-Heine University, Duesseldorf	Phase 2
Galderma	N/A

See all mirvaso clinical trials

Pharmacology for mirvaso

Drug Class	alpha-Adrenergic Agonist
Mechanism of Action	Adrenergic alpha-Agonists

Paragraph IV (Patent) Challenges for MIRVASO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
MIRVASO	Topical Gel	brimonidine tartrate	0.33%	204708	1	2014-12-15

US Patents and Regulatory Information for mirvaso

mirvaso is protected by twelve US patents.

Patents protecting mirvaso

Brimonidine gel compositions and methods of use
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Compounds, formulations, and methods for treating or preventing rosacea
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA

Brimonidine gel composition
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA

Gel compositions and methods of use
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Compounds, formulations, and methods for ameliorating telangiectasis
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Methods and compositions for treating or preventing erythema
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA

Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA

Methods and compositions for safe and effective treatment of erythema
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Galderma Labs Lp	MIRVASO	brimonidine tartrate	GEL;TOPICAL	204708-001	Aug 23, 2013	AB	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Galderma Labs Lp	MIRVASO	brimonidine tartrate	GEL;TOPICAL	204708-001	Aug 23, 2013	AB	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Galderma Labs Lp	MIRVASO	brimonidine tartrate	GEL;TOPICAL	204708-001	Aug 23, 2013	AB	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Galderma Labs Lp	MIRVASO	brimonidine tartrate	GEL;TOPICAL	204708-001	Aug 23, 2013	AB	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for mirvaso

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Galderma Labs Lp	MIRVASO	brimonidine tartrate	GEL;TOPICAL	204708-001	Aug 23, 2013	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for mirvaso

See the table below for patents covering mirvaso around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
European Patent Office	2815748	Composés, formulations et procédés pour traiter ou prévenir la rosacée (Compounds, formulations, and methods for treating or preventing rosacea)	⤷ Sign Up
Japan	5747391		⤷ Sign Up
China	103298472	Improved methods and compositions for safe and effective treatment of erythema	⤷ Sign Up
Israel	225760	תכשירי ג'ל ברימונידי (Brimonidine gel compositions)	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Supplementary Protection Certificates for mirvaso

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1631293	C300683	Netherlands	⤷ Sign Up	PRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225
1631293	191 5019-2014	Slovakia	⤷ Sign Up	PRODUCT NAME: BRIMONIDIN; REGISTRATION NO/DATE: EU/1/13/904/001 - EU/1/13/904/003 20140221
1631293	1490049-2	Sweden	⤷ Sign Up	PRODUCT NAME: BRIMONIDIN OCH FARMACEUTISKA SALTER DAERAV; REG. NO/DATE: EU/1/13/904 20140221
1631293	2014/041	Ireland	⤷ Sign Up	PRODUCT NAME: BRIMONIDINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/904 20140221
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description